Comparative Efficacy of Floss and Essential Oil/CPC+Zn Mouthwashes in Reducing Dental Plaque and Gingivitis

Colgate Palmolive228 enrolled

Overview

The objective of this clinical research study is to evaluate the efficacy of floss to an essential oil alcohol-containing mouthwash, an essential oil alcohol-free mouthwash, and a CPC+Zn alcohol-free mouthwash in reducing dental plaque and gingivitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

228

Conditions

Dental Plaque Gingivitis

Interventions

MouthwashDRUG

Antiplaque/Antigingivitis Mouthwash

FlossDEVICE

Dental Floss

ToothbrushDEVICE

Soft bristled, manual toothbrush

Toothpaste

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female volunteers at least 18 years of age and in general good health. * Willing and able to understand and sign the informed consent form. * Whole mouth mean MGI ≥1.95, whole mouth mean TPI≥1.95, and ≥10% bleeding sites * Be willing to conform to the study protocol and procedures. * No sites with probing depth \>4 mm. * Minimum of 20 natural teeth with scorable facial and lingual surfaces Exclusion Criteria: * Medical condition which requires premedication prior to dental visits/procedure. * Known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the study examiner. * Active disease of the hard oral tissues. * Significant oral soft tissue pathology, excluding plaque-induced gingivitis. * Moderate to severe periodontitis (stages II-IV) per the EFP S3 guidelines. * Subjects with fixed or removable orthodontic appliances or removable partial dentures. * Dental prophylaxis within 30 days prior to study start. * Use of antibiotics, antimicrobial drugs, anti-inflammatory drugs, or anticoagulant therapies within 30 days prior to study start. * Use of chemotherapeutic oral care products within two weeks prior to study start. * Participation in any other clinical study within 30 days prior to enrollment into this study. * Subjects who must receive dental treatment during the study dates. * Immunocompromised individuals (HIV, AIDS, immunosuppressive drug therapy). * Use of smokeless tobacco, vaping, or e-cigarettes or suspected substance abuse. * Current smokers (if former smoker, should have stopped at least 1 month prior to Visit 1) * Pregnant or lactating subjects, or subjects planning to become pregnant during the course of the study. * Medical condition which prohibits not eating/drinking or chewing gum for four (4) hours prior to your scheduled visits; * Subjects who have an infectious disease and/or other blood borne diseases (Hepatitis series, HIV, tuberculosis).

Locations (1)

Salus Research, Inc.

Fort Wayne, Indiana, United States

Outcomes

Primary Outcomes

Interproximal mean Modified Gingival Index (MGI)

MGI will be visually assessed for six sites for each graded tooth (mesiofacial, facial, distofacial, mesiolingual, lingual, distolingual). Interproximal MGI includes the mesiofacial, distofacial, mesiolingual, and distolingual sites. Higher scores indicate a worse outcome, per below. 0 = no inflammation; no redness 1. = mild inflammation; slight changes in color and texture, but not in all portions of gingival marginal or papillary 2. = mild inflammation; slight changes in color and texture in all portions of gingival margin or papillary 3. = moderate inflammation; bright surface inflammation, erythema, edema, and/or hypertrophy of gingival marginal or papillary 4. = severe inflammation; erythema, edema, and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion, or ulceration

Time frame: 12 weeks

Secondary Outcomes

Whole Mouth mean Modified Gingival Index (MGI)

MGI will be visually assessed for six sites for each graded tooth (mesiofacial, facial, distofacial, mesiolingual, lingual, distolingual). Whole Mouth MGI includes all six sites. Higher scores indicate a worse outcome, per below. 0 = no inflammation; no redness 1. = mild inflammation; slight changes in color and texture, but not in all portions of gingival marginal or papillary 2. = mild inflammation; slight changes in color and texture in all portions of gingival margin or papillary 3. = moderate inflammation; bright surface inflammation, erythema, edema, and/or hypertrophy of gingival marginal or papillary 4. = severe inflammation; erythema, edema, and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion, or ulceration

Time frame: 1, 4, and 12 weeks

Interproximal mean Turesky Modification of the Quigley-Hein Plaque Index (TPI)

Dental plaque will be assessed at six sites for each graded tooth (mesiofacial, facial, distofacial, mesiolingual, lingual, distolingual) and scored as follows: 0=No plaque 1. Separate flecks of plaque at the cervical margin 2. A thin, continuous band of plaque (up to 1 mm) at the cervical margin 3. A band of plaque wider than 1 mm, but covering less than 1/3 of the side of the crown of the tooth 4. Plaque covering at least 1/3, but less than 2/3 of the side of the crown of the tooth 5. Plaque covering 2/3 or more of the side of the crown of the tooth Interproximal mean includes mesiofacial, distofacial, mesiolingual, and distolingual sites. Higher scores indicate a worse outcome, per above.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.